Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30

뉴스 본문을 불러오고 있어요.

Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30 | 웨이프 WAPE

Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30

기사 요약

관련 종목

댓글 —